TS
FNCH

Thomas Steyer’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Thomas Steyer’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,178
Closed -$2.61M – 316
2021
Q2 		$2.61M Sell
6,178
-6,822
-52% -$2.95M 0.01% 202
2021
Q1 		$6.21M Buy
+13,000
New +$6.62M 0.03% 173

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
LSCM
Light Street Capital Management Palo Alto, California $903M AUM 113.12% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
TA
TRB Advisors New York $233M AUM 14.81% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return

Thomas Steyer's FNCH Position: Q3 2021 in Review

Thomas Steyer sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q3 2021, closing a stake of 6,178 shares — an estimated $2.61M sold.

Thomas Steyer first reported a position in FNCH in Q1 2021 and held it in 2 quarters. The position peaked at $6.21M in Q1 2021. 44 funds tracked by Wall St. Rank hold FNCH as of Q3 2021.

  • Thomas Steyer reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Thomas Steyer sold 6,178 Finch Therapeutics Group, Inc. Common Stock shares in Q3 2021, an estimated $2.61M.
  • Thomas Steyer first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Thomas Steyer's Finch Therapeutics Group, Inc. Common Stock position peaked at $6.21M in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q3 2021.

Based on Farallon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.